5) Sarkozy!C,!Chong!L,!Takata!K,!Chavez!EA,!Miyata>Takata!T,!Duns!G,!Telenius!A,!Boyle!M,!Slack!GW,!
Laurent! C,! Farinha! P,! Molina! TJ,! Copie>Bergman! C,! Damotte! D,! Salles! GA,! Mottok! A,! Savage! KJ,!
Scott!DW,!Traverse>Glehen!A,!Steidl!C.!Gene!expression!profiling!of!gray!zone!lymphoma.!Blood!
Adv.!2020;!4:2523>2535.!
6) Sarkozy! C,! Hung! SS,! Chavez! EA,! Duns! G,! Takata! K,! Chong! LC,! Aoki! T,! Jiang! A,! Miyata>Takata! T,!
Telenius! A,! Slack! GW,! Molina! TJ,! Ben>Neriah! S,! Farinha! P,! Dartigues! P,! Damotte! D,! Mottok! A,!
Salles!GA,!Casasnovas!RO,!Savage!KJ,!Laurent!C,!Scott!DW,!Traverse>Glehen!A,!Steidl!C.(Mutational!
Landscape!of!Grey!Zone!Lymphoma.(Blood.!2020;!E>pub!ahead!of!print.!
7) Pilichowska! M,! Pittaluga! S,! Ferry! JA,! Hemminger! J,! Chang! H,! Kanakry! JA,! Sehn! LH,! Feldman! T,!
Abramson!JS,!Kritharis!A,!Hernandez>Ilizaliturri!FJ,!Lossos!IS,!Press!OW,!Fenske!TS,!Friedberg!JW,!
Vose! JM,! Blum! KA,! Jagadeesh! D,! Woda! B,! Gupta! GK,! Gascoyne! RD,! Jaffe! ES,! Evens.!
Clinicopathologic! consensus! study! of! gray! zone! lymphoma! with! features! intermediate! between!
DLBCL!and!classical!HL.!Blood!Adv.!2017;!1:2600>2609.!
! !
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES